Revolutionary Liquid Biopsy Platform

Our proprietary platform leverages the natural stability of exosomes, tiny vesicles that protect genetic material in the bloodstream with a 1-week half-life (versus just 2 hours for conventional ctDNA).

Technology Comparison

Technology Advantages

10,000x greater sensitivity than traditional methods
‍
>97% sensitivity across all cancer stages

24-hour results

ExoDiscovery collaborates with world-class medical centers and research institutions.

Unprecendented Perfomance

Early Detection.
Precise Monitoring.
1-Day Results.

Transforming cancer care
ExoDiscovery makes cancer diagnostics precise and timely with our proprietary exosome-based liquid biopsy platform. It provides you with actionable insights for both detection and monitoring without the wait.
‍
Real-time cancer intelligence flows naturally through ExoDiscovery's ultra-sensitive molecular beacon technology and digital droplet detection, enabling earlier intervention and more effective treatment monitoring.

>97% sensitivity and 96.1% specificity in clinical validation studies.

As published in ACS Nano (2025) and validated in our expanded 120+ lung cancer patient study.

What makes our platform a better choice?

ExoDiscovery's platform transforms cancer detection and monitoring with unprecedented speed and sensitivity.

ExoDiscovery Platform

Speed

24-hour turnaround time

Sensitivity

10,000x greater detection capability

Efficiency

No amplification required

Sample Size

Minimal 20μL plasma

Cost

Competitive test pricing

Conventional Methods

Speed

7-14 day waiting period

Sensitivity

Limited detection threshold

Efficiency

Complex PCR/NGS processing

Sample Size

10-20mL required

Cost

Higher testing expenses

VS

Contact Us

ExoDiscovery Technology
Transforming Cancer Diagnostics

Streamline clinical pathways with RNA-based exosome detection technology designed to integrate with standard blood collection protocols, requiring minimal sample volume while delivering exceptional cancer signal detection capabilities.

Rapidly detect cancer mutations from a single 20μL plasma sample with our proprietary digital detection system, delivering comprehensive mutation profiles within 24 hours, dramatically faster than 7-14 day conventional methods.

Design optimal treatment plans with our advanced longitudinal tracking tools that monitor mutation trends over time, enabling earlier detection of resistance mutations and more informed therapy decision-making.

Generate actionable insights with our powerful analytical platform that presents mutation data, variant allele frequencies, and clinical significance in clear, intuitive formats for more confident clinical decisions.

Prepare for evolving needs with our scalable biomarker platform built to expand from initial EGFR and KRAS mutation detection to a comprehensive panel including MET, BRAF, ROS1, RET and additional mutations in development.

Simplify patient care with a minimally invasive approach that complements and can reduce tissue biopsies in many scenarios, providing comprehensive molecular information through a simple blood draw.

FAQ

What is ExoDiscovery technology?

ExoDiscovery technology is a revolutionary exosome-based liquid biopsy platform that analyzes RNA biomarkers protected within naturally occurring exosomes in blood. Unlike conventional approaches that rely on circulating tumor DNA (ctDNA) with a 2-hour half-life, our technology leverages exosomes' natural 1-week half-life to deliver 10,000x greater sensitivity with results in just 24 hours.

How does ExoDiscovery differ from conventional liquid biopsy methods?

ExoDiscovery's platform analyzes RNA within exosomes rather than circulating tumor DNA, providing several key advantages: 1) Higher sensitivity (10,000x greater than conventional methods), 2) Faster results (24 hours vs. 7-14 days), 3) Smaller sample requirements (only 20μL of plasma vs. 10-20mL), and 4) No amplification needed, which eliminates PCR/NGS-related errors and complexity.

What are the clinical applications of ExoDiscovery technology?

ExoDiscovery offers two primary applications: 1) ExoDiscovery Detect for early cancer screening in high-risk populations, and 2) ExoDiscovery Monitor for tracking treatment response and detecting resistance mutations in cancer patients. Both applications leverage the same core technology with specialized biomarker panels for each purpose.

How does ExoDiscovery help with cancer treatment decisions?

ExoDiscovery Monitor provides quantitative tracking of cancer mutations over time, allowing oncologists to detect emerging resistance EGFR and KRAS mutations before they would be visible on imaging. This early detection capability enables more timely treatment adjustments, potentially improving patient outcomes by detecting treatment failure earlier than conventional methods.

What types of cancer can ExoDiscovery technology detect and monitor?

Our initial focus is on lung cancer, with validation for EGFR mutations (L858R, T790M) and KRAS. We're expanding to include other actionable mutations including MET amplification, BRAF, ROS1, and RET. Future development includes additional cancer types, with pancreatic cancer in our near-term pipeline through collaboration with MD Anderson Cancer Center.

What clinical validation has been completed for ExoDiscovery technology?

ExoDiscovery technology has been validated in clinical studies:
EGFR: 116 samples with 95% sensitivity and >99.9% specificity
KRAS: 101 samples with 94% sensitivity and 99.9% specificity

Our studies include an 83-patient validation cohort and an expanded 120+ lung cancer patient study. Results have been published in the prestigious journal ACS Nano (2025) and validated through collaborations with leading medical centers.

How does sample collection work for ExoDiscovery tests?

ExoDiscovery tests require standard blood collection using EDTA tubes, collecting just 200μL of plasma (analyzing only 20μL). The samples are processed using our proprietary digital droplet detection technology, with no special handling requirements at collection sites. This makes the test easy to integrate into existing clinical workflows.